InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Discover the detailed record of transactions filed by Hoffmann Bernhard. Director active across 2 companies, notably Ocuphire Pharma, Inc.. Cumulatively, 5 reports have been published. Activity tracked since 10 January 2023. The latest transaction was disclosed on 13 March 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 条申报中的 5 条
Hoffmann Bernhard is a declarant linked to Ocuphire Pharma, Inc. and Opus Genetics, Inc., where he holds the role of SVP of Corp. Dev. His record shows 5 filings in total, and across the 5 most recent filings covered here the transaction nature is listed as Attribution, with amounts of EUR 12,038.69978638249 on 2024-01-12 at Ocuphire Pharma, Inc. and EUR 7,452.171905467626 on 2025-02-06 at Opus Genetics, Inc., spanning 2023-01-12 to 2025-03-17.